Probiotics for the prostate: every trial, and what none of them shows
No human randomised controlled trial of any probiotic strain in men with benign prostatic hyperplasia is indexed in PubMed, and no interventional probiotic study in BPH or male LUTS is registered on ClinicalTrials.gov. That was independently replicated on 29 July 2026 with MeSH-anchored and free-text sweeps (42 and 50 hits; 8 and 5 after trial filters; none in BPH) and three ClinicalTrials.gov API v2 queries (0, 0 and 9 hits, none in BPH or male LUTS). Scope, stated plainly: PubMed and ClinicalTrials.gov. Non-US registries were not systematically searched.
The prostate, BPH and urinary-flow evidence in full. The absence statement at the top carries the databases actually searched, in its own first sentence, because an absence with no scope is not a finding.
Are probiotics good for the prostate?
There is no demonstrated benefit. No human RCT of any probiotic strain in men with BPH is indexed in PubMed, and no interventional probiotic study in BPH or male LUTS is registered on ClinicalTrials.gov. The strain pair marketed hardest for prostate health has never been given to a human being for a prostate outcome — its entire evidence base is one cell-culture study authored by an employee and a co-founder of a probiotic company (PMID 39594064 (opens in a new tab)).
Prostate, BPH and urinary flow
The strain pair marketed hardest for prostate health has never been given to a single human being for a prostate outcome. Every "reduces DHT / lowers PSA / cuts prostate inflammation 5-fold" claim in this category traces to one dish of cells — a CaCo-2 + RWPE-1 + WPMY-1 co-culture with BPH simulated by DHT, using B. longum subsp. longum novaBLG1 (DSM 34338) and B. psychraerophilum Q5 (DSM 33131). ROS down ~6×, IL-6 and IL-10 down ~5×, DHT down ~10×, PSA "75% improvement." One author is employed by Noivita Srls, another is its co-founder, and the strains were donated by Probionova SA. Zero humans, zero animals (PMID 39594064 (opens in a new tab), Foods 2024;13(22):3647). The paper also contradicts itself on funding — the Funding statement says "This research received no external funding" while grant ECS00000036 appears in the Acknowledgments.
The closest thing to a rigorous test of the gut-bacteria→prostate chain in real BPH patients failed on every endpoint. S-equol — the bacterial metabolite itself, not a probiotic — in 116 men aged ≥50 with IPSS>13, prostate volume 20–70 mL and Qmax 5–15 cc/s, four arms of 29. Primary endpoint (change in PSA at 4 weeks, ANCOVA): 10 mg p=0.4678, 50 mg p=0.4892, 150 mg p=0.8185 — and placebo produced the largest PSA fall. IPSS change −5.81 / −6.18 / −4.15 versus placebo −5.96. DHT +64.2 / −6.2 / +68.1 versus placebo −14.5 pg/mL — no suppression at all. Nocturia median 3.0 in all four arms. Sponsor Ausio Pharmaceuticals LLC; completed January 2016, results posted May 2017, never published in a peer-reviewed journal (NCT00962390 (opens in a new tab)).
The only trial anywhere comparing a probiotic alone against placebo and reporting IPSS in men was null. L. casei DG® at 24×10⁹ CFU/day versus placebo in chronic bacterial prostatitis, n=24 (12/12), men 18–55, all pre-treated with a month of ciprofloxacin: IPSS between-group p=0.546 (PMID 39858898 (opens in a new tab)). One note on the strain identity, because it matters on a page whose premise is that a designator is a scientific claim: the code CNCM I-1572 does not appear anywhere in that paper. It is an inference from the Sofar/Enterolactis literature and is labelled here as one.
And the plant actives bundled into "prostate" probiotics have already failed at higher doses than the probiotics contain. Saw palmetto: 32 RCTs, 5,666 men, AUA symptom score MD 0.25 (95% CI −0.58 to 1.07) across three high-quality long-term trials; peak urine flow MD 0.40 mL/s (−0.30 to 1.09) (PMID 23235581 (opens in a new tab)). CAMUS escalated 369 men from 320 to 960 mg/day over 72 weeks and reported a group mean difference of 0.79 favouring placebo, one-sided P=0.91 (PMID 21954478 (opens in a new tab)). The 2023 Cochrane update reports IPSS MD −0.90 (−1.74 to −0.07) at high certainty, describing it as "little to no difference" — statistically significant, clinically trivial (CD001423.pub4). Lycopene: PSA MD −0.34 (−2.01 to 1.32) across 3 RCTs and 154 participants (PMID 22071840 (opens in a new tab)). Men's probiotics dose saw palmetto at 80–303 mg — a quarter of a dose that already failed.
Selenium, which appears in several men's formulas, has a documented harm signal. SELECT, n=35,533 men: prostate-cancer HR 1.04 (99% CI 0.87–1.24) at 200 µg/day (PMID 19066370 (opens in a new tab)). The case-cohort follow-up found +91% high-grade prostate cancer (Gleason 7–10) among men with higher baseline selenium status, P=.007, and concludes verbatim: "Men should avoid selenium or vitamin E supplementation at doses that exceed recommended dietary intakes" (PMID 24563519 (opens in a new tab)).
Where these outcomes sit in the 22-row table
The grade is assigned on the hub’s 22-row table and argued above. The row s are reproduced here unchanged, so the grade a reader quotes from this page is the same grade the table carries. What a grade measures is set out under how the grades work: it is a statement about the strength of the evidence for a named strain, never a statement that a product does anything.
| # | Outcome | Best grade at strain level | The strain, and the trial behind it | Buyable at the dose that was studied? |
|---|---|---|---|---|
| 14 | Prostate, BPH, LUTS, PSA | Grade F for **Prostate, BPH, LUTS, PSA** — nothing qualifies | — | Nothing qualifies |
| 15 | Chronic prostatitis (probiotic alone) | Grade F for **Chronic prostatitis (probiotic alone)** — nothing qualifies | — | Nothing qualifies |
The strains named above, and the labels in this audit that print them
Every row below is a line on a printed supplement panel, read off that product’s own teardown. A panel printing a designator is a fact about the panel. It is not evidence that the product was tested, that it delivers the amount that was studied, or that the strain does anything — several of the paragraphs above say in terms that it does not, and the dose is unknowable wherever the panel gives no per-organism quantity.
- B. longum subsp. longum novaBLG1 (DSM 34338)
-
Not printed on any panel this audit has transcribed.
- B. psychraerophilum Q5 (DSM 33131)
-
Not printed on any panel this audit has transcribed.
- L. casei DG®
-
Not printed on any panel this audit has transcribed.
Read next
- Probiotics and testosterone in men: the whole chain, end to end The claim starts in one mouse study, and the same strain then failed in men in a trial run by the company that sells it. Every link in the chain.
- Probiotics and erectile function Not "no evidence exists" — the trials that exist are placebo-free, in the wrong populations, using unnamed strains, with unreported effect sizes.
- Probiotic safety, and who should not take them The pooled safety data are genuinely reassuring, and the literature that produced those nulls did not systematically look. Both halves, with the scope.
- The evidence hub All 22 outcomes in one table, the strain × outcome table, and every other outcome page.
- What to buy, and what not to The verdict, the five reasons a man arrives here, and the products ranked by how much their labels disclose. Two of the five reasons end in nothing.